First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter
Matthew J Price, Shigeru Saito, Richard A Shlofmitz, Douglas J Spriggs, Michael Attubato, Brent McLaurin, Alexandra Popma Almonacid, Sandeep Brar, Minglei Liu, Elizabeth Moe, Roxana Mehran, Matthew J Price, Shigeru Saito, Richard A Shlofmitz, Douglas J Spriggs, Michael Attubato, Brent McLaurin, Alexandra Popma Almonacid, Sandeep Brar, Minglei Liu, Elizabeth Moe, Roxana Mehran
Abstract
Objectives: The aim of this study was to explore the safety and efficacy of a dedicated drug-eluting stent for the treatment of coronary lesions with very small reference vessel diameter (RVD).
Background: Smaller RVD is associated with increased risk for restenosis and target lesion failure (TLF) after stent implantation.
Methods: This was a prospective, single-arm, multicenter trial of the Resolute Onyx 2.0-mm zotarolimus-eluting stent. The primary endpoint was 12-month TLF, which was compared with a pre-specified performance goal. Subjects with stable or unstable angina or ischemia, target lesions ≤27 mm in length, and RVD ≥2.0 and <2.25 mm were eligible for enrollment. A subset of subjects underwent follow-up angiography at 13 months post-procedure.
Results: A total of 101 subjects with 104 lesions were enrolled. The mean age was 67.3 ± 9.6 years, 47% of subjects had diabetes, the mean lesion length was 12.6 ± 6.3 mm, and the mean RVD was 1.91 ± 0.26 mm. The rate of TLF at 12 months was 5.0%, fulfilling the pre-specified performance goal of 19% (p < 0.001). The rates of target lesion revascularization and target vessel myocardial infarction were 2.0% and 3.0%, respectively. There were no episodes of stent thrombosis. In-stent late lumen loss was 0.26 ± 0.48 mm, and the rate of binary restenosis was 12.0%.
Conclusions: In this first report of a drug-eluting stent with a dedicated size to treat lesions with RVD <2.25 mm, the Resolute Onyx 2.0-mm zotarolimus-eluting stent was associated with a low rate of TLF and late lumen loss, without a signal for stent thrombosis. This novel-sized drug-eluting stent appears to be a feasible option for the treatment of coronary lesions in extremely small vessels. (Medtronic Resolute Onyx 2.0 mm Clinical Study; NCT02412501).
Keywords: Resolute Onyx; drug-eluting stent(s); percutaneous coronary intervention; reference vessel diameter; restenosis; stent(s); zotarolimus.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed